Imperial College London

DrNeloferSyed

Faculty of MedicineDepartment of Medicine

Senior Research Fellow
 
 
 
//

Contact

 

+44 (0)20 7594 5292n.syed

 
 
//

Location

 

E506Burlington DanesHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Chatziathanasiadou:2019:10.1016/j.jpba.2018.11.030,
author = {Chatziathanasiadou, MV and Stylos, EK and Giannopoulou, E and Spyridaki, M-H and Briasoulis, E and Kalofonos, HP and Crook, T and Syed, N and Sivolapenko, GB and Tzakos, AG},
doi = {10.1016/j.jpba.2018.11.030},
journal = {Journal of Pharmaceutical and Biomedical Analysis},
pages = {690--697},
title = {Development of a validated LC-MS/MS method for the in vitro and in vivo quantitation of sunitinib in glioblastoma cells and cancer patients},
url = {http://dx.doi.org/10.1016/j.jpba.2018.11.030},
volume = {164},
year = {2019}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - Sunitinib is a multi-targeted tyrosine kinase inhibitor approved for the treatment of renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumor and is currently being investigated against other forms of malignant tumors. Recently great interest has emerged for the application of sunitinib to glioblastoma treatment. In order to have a method with broad applicability it will be of importance to have access to a method that could be applied both in human plasma and cell uptake studies. No method has been reported thus far for the estimation of sunitinib uptake in glioma cells. We therefore set out to develop a method that could be applied for quantifying sunitinib in human plasma and in cell uptake studies. The method was validated and accredited according to ISO 17025:2005 guideline in human plasma and successfully applied to cancer patient plasma. Also, the method was effectively recruited to establish a protocol for the evaluation of sunitinib accumulation into M095K glioma cells. This method could significantly contribute to developmental phases in repurposing this drug in different cancer types.
AU - Chatziathanasiadou,MV
AU - Stylos,EK
AU - Giannopoulou,E
AU - Spyridaki,M-H
AU - Briasoulis,E
AU - Kalofonos,HP
AU - Crook,T
AU - Syed,N
AU - Sivolapenko,GB
AU - Tzakos,AG
DO - 10.1016/j.jpba.2018.11.030
EP - 697
PY - 2019///
SN - 0731-7085
SP - 690
TI - Development of a validated LC-MS/MS method for the in vitro and in vivo quantitation of sunitinib in glioblastoma cells and cancer patients
T2 - Journal of Pharmaceutical and Biomedical Analysis
UR - http://dx.doi.org/10.1016/j.jpba.2018.11.030
UR - https://www.ncbi.nlm.nih.gov/pubmed/30472587
UR - http://hdl.handle.net/10044/1/66375
VL - 164
ER -